Context-Dependent Glioblastoma–Macrophage/Microglia Symbiosis and Associated Mechanisms
Glioblastoma (GBM) is a lethal form of primary brain tumor in human adults. The impact of tumor-intrinsic alterations is not exclusively confined to cancer cells but can also be extended to the tumor microenvironment (TME). Glioblastoma-associated macrophages/microglia (GAMs) are a prominent type of...
Gespeichert in:
Veröffentlicht in: | Trends in immunology 2021-04, Vol.42 (4), p.280-292 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Glioblastoma (GBM) is a lethal form of primary brain tumor in human adults. The impact of tumor-intrinsic alterations is not exclusively confined to cancer cells but can also be extended to the tumor microenvironment (TME). Glioblastoma-associated macrophages/microglia (GAMs) are a prominent type of immune cells that account for up to 50% of total cells in GBM. Emerging evidence suggests that context-dependent GBM–GAM symbiotic interactions are pivotal for tumor growth and progression. Here, we discuss how specific genetic alterations in GBM cells affect GAM biology and, reciprocally, how GAMs support GBM progression. We hypothesize that understanding context-dependent GBM–GAM symbiosis may reveal the molecular basis of GBM tumorigenesis and lead to novel candidate treatment approaches aiming to improve GBM patient outcomes.
Symbiotic glioblastoma–macrophage/microglia (GBM–GAM) interactions reveal synthetic lethality in GBM harboring a deficiency in a specific tumor suppressor gene (e.g., PTEN, NF1, or TP53).Cancer cell-intrinsic activation of oncogenes (e.g., EGFR and CLOCK) can shape a protumor immune response by modulating GAM biology.GBM–GAM symbiosis can contribute to GBM progression by promoting glioma stem cell (GSC) stemness, GBM cell proliferation, survival, and migration as well as by suppressing T cell-mediated immune responses in mouse and patient-derived xenograft (PDX) models.Characterizing GBM–GAM symbiosis might reveal personalized therapeutic targets. For example, LOX and CLOCK inhibition can impair tumor progression and GAM infiltration, specifically in PTEN-deficient and CLOCK-high GBM in mouse and PDX models, respectively. |
---|---|
ISSN: | 1471-4906 1471-4981 |
DOI: | 10.1016/j.it.2021.02.004 |